CA3070505C — Formulations of a compound modulating kinases

USPTO Abstract

Provided herein are compositions composition comprising 40% to about 60% W/W of a crystalline HC1 salt of Compound I, wherein the crystalline HC1 salt of Compound I has an X-ray powder diffractogram comprising peaks (0).2 ) at 7.3, 23.3 and 28.2 '20 as determined on a diffractometer using Cu-Kct radiation; 20% to 35% W/W of poloxamer 407; 10% to 22% W/W of mannitol; 1% to 5% W/W of crospovidone; and 0.5% to 3% W/W of magnesium stearate. Methods of making and using same are also disclosed. The described compositions are useful for treating diseases and conditions modulated by CSF1R, c-Kit and/or FLT3, and have improved dissolution profiles.